secwatch.observer — SEC 8-K summary
======================================

Issuer:     WINDTREE THERAPEUTICS INC /DE/ (WINT)
CIK:        0000946486
Form:       8-K/A
Filed at:   2025-03-25T23:59:59+00:00
Accession:  0001437749-25-009203
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Windtree signs sourcing deal for Evofem's FDA-approved PHEXXI contraceptive gel
-------------------------------------------------------------------------------

- License and Supply Agreement makes Windtree sourcing partner for Evofem's PHEXXI (hormone-free vaginal gel).
- PHEXXI generated >$19M revenue in FY2024; 96,000 boxes of 12 applicators sold.
- Windtree aims to cut manufacturing costs via its contacts, aiding Evofem's global expansion.
- Saundra Pelletier is CEO of Evofem and also serves on Windtree's board of directors.
- Deal is first step in Windtree's new strategy to become a revenue-generating biotech.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946486/000143774925009203/0001437749-25-009203-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946486/000143774925009203/wint20250324_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-009203

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer